Sector News

Martha Marsh appointed to Edwards Lifesciences board

October 23, 2015
Life sciences

/PRNewswire/ – Edwards Lifesciences Corporation, the global leader in the science of heart valves and hemodynamic monitoring, today announced that Martha H. Marsh has been appointed to its board of directors.

Marsh served as the president and CEO of Stanford Hospital & Clinics for eight years, until her retirement in 2010. Prior to joining Stanford, Marsh served in hospital leadership positions at University of California Davis Medical Center, University of Pennsylvania Health System and Dartmouth-Hitchcock Medical Center.

“Martha is a welcome addition to our board of directors, which will benefit from her 30 years of experience and insight into serving patients in an increasingly complex and ever-evolving healthcare system,” said Michael A. Mussallem, Edwards’ chairman and CEO. “Martha’s deep knowledge and unique leadership will add a valuable perspective as our board considers the execution of our patient-focused innovation strategy.”

Currently, Marsh serves on the boards of directors of AMN Healthcare Services, Inc., and Owens & Minor Inc., a leading healthcare logistics company. She also served on the board of Thoratec Corp. until its Oct. 8 acquisition by St. Jude Medical, Inc.

Marsh has master’s degrees in public health administration and accounting from Columbia University and a bachelor’s degree in history from the University of Rochester.

Source: Edwards Lifesciences Corporation

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach